For adenoviral transfection, neonatal cardiac myocytes were infected with adenovirus pAdEasy1-WT-ASK1 (expressing GFP and WT-ASK1 under separate CMV promoters) at an MOI of 50 using a viral stock of titre 10 10 viral particles/ml.
Gene delivery to cells can be accomplished by using viral and non-viral vectors.
GMP-complaint manufacture and release of T cells can be accomplished using viral and non-viral methods.
It is well appreciated that the human T-cell response can be modified using viral and non-viral vectors to promote the selective targeting of cancer cells by introducing exogenous T-cell receptors (TCRs) or chimeric antigen receptors (CARs) [ 161].
Primary human T cells can be modified using viral and non-viral vectors to promote the specific targeting of cancer cells via the introduction of exogenous T-cell receptors (TCRs) or chimeric antigen receptors (CARs).
Viral RNAs were extracted from the viral isolates using a QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA, USA) and stored at −80°C for further use.
Because all of the aforementioned measures indicated that BYDV was an RNA virus, viral RNAs were extracted using a QIAamp Viral RNA Mini kit (Qiagen) following the manufacturer's protocol.
Viral RNA was extracted from clinical specimens and viral cultures using a QIAamp Viral RNA Mini Kit (Qiagen, Germany) according to the manufacturer's instructions.
For the sequencing of the VP1 (viral protein 1) gene, viral RNA was extracted using a QIAamp Viral RNA Mini Kit (Qiagen, Santa Clara, CA).
Viral RNAs were extracted using a QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA, USA) from a 140 µL volume specimen.
From 140 μL of this diluted stool sample, viral RNA was extracted using a QIAamp viral RNA mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
